|
Post by RLC on Apr 23, 2015 14:37:31 GMT
Website was redesigned: oncosec.com/Here's a snippet from their Pipeline. Nice to see them sort of highlight the combo study with Merck:
|
|
|
Post by JHam on Apr 27, 2015 13:12:46 GMT
|
|
|
Post by actcfan on Apr 27, 2015 17:30:21 GMT
Any thoughts on why the bounce back today?
|
|
|
Post by RLC on Apr 27, 2015 17:43:31 GMT
Any thoughts on why the bounce back today? Only to sell or not to sell I have no clue what's causing the move, but am happy to see it! I'd imagine once the balls gets rolling on the combo study, this could start finding a new floor (hopefully much higher than the $0.26 - $0.30 we've been at).
|
|
|
Post by RLC on May 6, 2015 15:29:01 GMT
Seeing some interesting activity (was up almost 20% earlier) here on this news: finance.yahoo.com/news/vista-partners-updates-coverage-oncosec-130000110.htmlFrom the article: Mr. Silver concludes, "ONCS entered into a clinical collaboration with the University of California, San Francisco (UCSF) in November, to evaluate the safety, tolerability and efficacy of the combination of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, and OncoSec's ImmunoPulse (intratumoral IL-12) in metastatic melanoma. According to ONCS, recent data suggest that patients who are PD-L1 positive and have increased tumor-infiltrating lymphocytes (TILs) are more likely to respond to anti-PD-1/PD-L1 mAbs compared to patients who are PD-L1 negative. Therefore, therapies that promote TIL generation and PD-L1 positivity may play an important role in augmenting the clinical efficacy of these agents. According to ONCS, patients are expected to be enrolled within the next 60 days and enrollment is scheduled to be completed within 12 months."
|
|
|
Post by actcfan on May 6, 2015 16:29:40 GMT
Seeing some interesting activity (was up almost 20% earlier) here on this news: finance.yahoo.com/news/vista-partners-updates-coverage-oncosec-130000110.htmlFrom the article: Mr. Silver concludes, "ONCS entered into a clinical collaboration with the University of California, San Francisco (UCSF) in November, to evaluate the safety, tolerability and efficacy of the combination of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, and OncoSec's ImmunoPulse (intratumoral IL-12) in metastatic melanoma. According to ONCS, recent data suggest that patients who are PD-L1 positive and have increased tumor-infiltrating lymphocytes (TILs) are more likely to respond to anti-PD-1/PD-L1 mAbs compared to patients who are PD-L1 negative. Therefore, therapies that promote TIL generation and PD-L1 positivity may play an important role in augmenting the clinical efficacy of these agents. According to ONCS, patients are expected to be enrolled within the next 60 days and enrollment is scheduled to be completed within 12 months."Nice move today. Now I'm wondering to sell or not to sell.
|
|
|
Post by dayanand33 on May 6, 2015 19:45:57 GMT
Opened a position for the first time at $0.285 . Since .30 was broken for the first time, I am hoping it retraces back shortly in the low.30s . If that happens I 'll sell. If it dips 20% from here, I may buy more. I think cult stocks are a safer bet for buying into the dips. Per plan, sold my position at $ 0.31 for ~9% profit. Will buy again if it drops to mid twenties
|
|
|
Post by RLC on May 7, 2015 15:05:28 GMT
Seeing some interesting activity (was up almost 20% earlier) here on this news: finance.yahoo.com/news/vista-partners-updates-coverage-oncosec-130000110.htmlFrom the article: Mr. Silver concludes, "ONCS entered into a clinical collaboration with the University of California, San Francisco (UCSF) in November, to evaluate the safety, tolerability and efficacy of the combination of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, and OncoSec's ImmunoPulse (intratumoral IL-12) in metastatic melanoma. According to ONCS, recent data suggest that patients who are PD-L1 positive and have increased tumor-infiltrating lymphocytes (TILs) are more likely to respond to anti-PD-1/PD-L1 mAbs compared to patients who are PD-L1 negative. Therefore, therapies that promote TIL generation and PD-L1 positivity may play an important role in augmenting the clinical efficacy of these agents. According to ONCS, patients are expected to be enrolled within the next 60 days and enrollment is scheduled to be completed within 12 months."Nice move today. Now I'm wondering to sell or not to sell. Always the question on a green day with this one! You would think word about enrollment beginning for the combo study would help in building some support, but maybe it's too far out for the market's liking. I feel safe making the prediction that ONCS could EASILY be above $1 by years end.
|
|
|
Post by RLC on May 14, 2015 13:26:13 GMT
|
|
|
Post by RLC on May 14, 2015 13:45:14 GMT
Just filled up on a ton of shares under $0.25! I think it's hilarious how companies tend to fall so drastically on the announcement of a reverse split, especially considering this is for the purpose of getting them on NASDAQ. Makes no sense.... this is great news.
|
|
|
Post by hophead on May 14, 2015 13:56:10 GMT
Agree RLC. Anyone notice whenever an otc ticker announces a r/s and adds the d in it's name it goes up? ACTCD did well and so did NVIVD. I'm thinking same for this puppy...
|
|
|
Post by hophead on May 14, 2015 14:07:21 GMT
I think maybe it has to do with naked shorts having to cover when a reverse is enacted? not sure but I'm putting this theory to work for a quick and hopefully profitable trade...
|
|
|
Post by selluwud on May 14, 2015 14:40:45 GMT
I am going to stick my toe in as well. Just to make few bucks on the mechanics of this type of reverse split/uplist situation.
Got in at .24
Lets see what happens??
|
|
|
Post by hophead on May 14, 2015 14:43:50 GMT
I just remember with ACTCD that after the reverse there was a steady uptrend on high volume with no news. Seemed like a shorts squeeze or shorts covering. This stock has been beaten to a pulp just like ACTC was at that time. All imo of course...
|
|
|
Post by JHam on May 14, 2015 16:17:53 GMT
Wow! This a big surprise. This is something I have been calling for forever, but I thought they would have timed it with data or some major milestone. Might as well get it over with though and rip off the bandaid. Could be a rough patch ahead though until they have some news to beef things up and I am not sure if the start of the P2 studies will be enough. Either way, I may add some more today as the current market cap is a joke.
|
|
|
Post by JHam on May 14, 2015 16:50:37 GMT
Just sold some ATHX and added a chunk of ONCS at $.247. I would not be surprised to see some major volatility after the reverse/up-list, so i will hold off buying back my original position for now. But feel pretty good with a core amount at $60M market cap. Would be nice if they have some news to coincide with this, or if Dhillon has some investors lined up (small cough)
|
|
|
Post by dayanand33 on May 14, 2015 19:17:40 GMT
opened a small position at $0.245. Looking to trade it into the volatility.
|
|
|
Post by jckrdu on May 14, 2015 21:39:14 GMT
Started a position at .245 as well.
|
|
|
Post by RLC on May 14, 2015 22:02:39 GMT
For anyone that's interested, here is the CEO's blog in regards to the reverse split: oncosec.com/ceo-perspective-reverse-split-and-uplisting-2/OncoSec Medical Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital MarketOn behalf of OncoSec, I want to thank our shareholders for their ongoing support of our mission to develop novel intratumoral immunotherapies to treat cancer. To date, the company has never been stronger in terms of our ImmunoPulse™ technology, advanced clinical pipeline, and collaborations with academic and industry institutions. To reflect our leadership position in the immuno-oncology field, our Board of Directors has approved a 1-for-20 reverse stock split to achieve one of our corporate goals for 2015: uplisting to the NASDAQ Capital Market. By executing a reverse stock split, we aim to fulfill the necessary quantitative requirements to become a NASDAQ-listed company. Benefits of Reverse Stock Split and Proposed UplistingIf we are successful in becoming a NASDAQ-listed company, we intend to expand our shareholder base to long-term institutional and retail investors who are dedicated to OncoSec’s vision. Investors who are prohibited from investing in OTC companies with a share price below a certain threshold will now be able to become a part of OncoSec’s story. By listing our common stock on a national securities exchange, we believe we will be able to increase the stability of our stock and achieve fundamental growth. We hope to achieve the following goals with our decision: -Increase the company’s visibility by positioning OncoSec in the appropriate market space -Expand the validation of the company’s technology beyond the scientific population and collaborators to the investment community -Operate in a marketplace that aligns us with our peers in immuno-oncology and reflects our level of development Rationale for Reverse Stock SplitIt’s important to understand that companies may execute a reverse stock split for several different reasons. Many companies perform a reverse split to avoid delisting, or losing their status on a national securities exchange. Conversely, we are executing a reverse stock split with the intention of uplisting to a national securities exchange and supporting an upward trajectory for the company. In the past year, OncoSec has aligned our clinical pipeline with what we see as a great unmet medical need in oncology: converting anti-PD-1 non-responders to responders. Additionally, we have expanded our immuno-oncology pipeline to reflect a broad range of tumor indications, increased our R&D capabilities, and collaborated with several prominent medical centers and industry leaders. Based on this success, we believe now is the appropriate time to execute a reverse stock split, which we hope will allow us to elevate the company’s listing status and generate more value for our shareholders. As always, we aim to continue to advance our technologies with the goal of one day benefiting cancer patients everywhere. We look forward to keeping our shareholders informed following our reverse stock split and proposed uplisting. Thank you again for your continued confidence in our team. Punit Dhillon, CEO | President
|
|
|
Post by jckrdu on May 14, 2015 22:27:47 GMT
I like the fact that they'll only have 12 million shares issued after the reverse. Tiny float that'll help when positive news is announced.
Need to do a little more research on their cash position... do they have at least 12 months of cash on hand?
|
|